HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx...

FDA Recall #D-0099-2026 — Class II — October 10, 2025

Recall #D-0099-2026 Date: October 10, 2025 Classification: Class II Status: Ongoing

Product Description

HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.

Reason for Recall

Lack of Assurance of Sterility.

Recalling Firm

Samsung Bioepis Co., Ltd. — Yeonsu, N/A

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

5,518 packs (11,036 Syringes) 2 syringes/carton)

Distribution

Distributed only to one warehouse in NJ. with no further distribution

Code Information

Lot: F2505017, Expiry: 24-Jan-2027

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated